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Invasive lobular carcinoma of the breast: MRI-pathological correlation 





Background:  Invasive lobular carcinoma (ILC) is more often multifocal and bilateral 
than invasive ductal carcinoma. MRI is usually recommended for detection of all ILC 
sites. The performance of known diagnostic breast MRI criteria for ILC 
characterization has not been evaluated to date using bilateral mastectomy 
specimens as gold standard.  
Purpose: To determine the value of BI-RADS 2006 MRI criteria for ILC detection and 
characterization, using pathological examination of bilateral mastectomy specimens 
as the reference standard. 
Material and Methods: Between 2004 and 2007, we retrospectively included all 
patients with pathologically documented ILC referred to our institution for bilateral 
mastectomy and preoperative bilateral breast MRI. The location, diameter and 
characteristics (BI-RADS) of all lesions were compared with pathological findings. 
The sensitivity and positive predictive value of bilateral breast MRI for the diagnosis 
of ILC were calculated. Association of MRI BI-RADS categorical variables and 
characterization of ILC were assessed (Fisher exact test). 
Results: Among 360 patients treated for ILC in 2004-2007, 15 patients qualified for 
this study. Thirty-one ILC foci were found on pathological examination (30 ipsilateral 
and 1 contralateral tumor; mean diameter 23mm; range 2 to 60mm) and all were 
identified on MRI, with 90% of masses and 10% nonmasslike enhancements; MRI 
features significantly associated with ILC included absence of smooth margins 
(p=0,02) and rim-shaped enhancement (p=0,039). Enhancement kinetics of the 31 
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foci were evenly distributed among washout, plateau and persistent profiles. Eleven 
additional lesions were seen on MRI, mainly corresponding to fibrocystic disease; 
91% presented as masses and 9% had a washout profile.  
Conclusion: Based on the 2006 BI-RADS criteria, breast MRI shows a high 
sensitivity for ILC detection, at the expense of a 26% false positive rate, suggesting 
that a pathological proof by US- or MR-guided biopsy is required in case of 
suspicious MRI images in this context. 
 




Invasive lobular carcinoma (ILC) is the second most common breast malignancy after 
invasive ductal carcinoma (IDC), accounting for 5 to 20% of all breast cancers ( 1-3). 
Pathologically, ILC is characterized by diffuse infiltrative growth (4), with a stroma 
infiltrated by tumor cells arranged in a single row and no associated desmoplastic 
reaction (5), hindering its diagnosis by imaging methods (6). In Hilleren et al. study of 
137 mammographies in patients with ILC (7), the findings were normal or showed 
only subtle abnormalities in 20% of cases, while the reported sensitivity of breast 
ultrasound for ILC ranges from 68 to 88% (3, 5).  
Because of its diffuse infiltrative growth, ILC is generally larger than IDC at diagnosis 
(8). ILC is also more often multifocal (several lesions in the same quadrant) or 
multicentric (several lesions or one large lesion affecting more than one quadrant) 
than IDC (3, 5, 9), reaching up to 50% of multifocal/multicentric forms (7, 10) 
compared to reported 19% rates in IDC (10). ILC also has a greater tendency than 
IDC to be bilateral, with rates of 6 to 20% and 2%, respectively (11).   
Positive pathological margins after conservative surgery are more frequent in ILC 
than in IDC (8), leading to more frequent re-excision and local recurrence risk (12). 
Some authors have suggested that optimal pre-operative staging of ILC, including 
breast MRI, could improve patient outcome (12). MRI has been described as one of 
the most appropriate tools for ILC staging (3), because of its high sensitivity for ILC 
detection and staging (ranging from 95% (13) to 100% (14)) and its high negative 
predictive value (NPV) (ranging from 95% (13) to 100% (2, 5, 6, 14)). However, these 
values were based on core needle biopsies (CNB), lumpectomy or ipsilateral 
mastectomy specimens. On CNB, it can be difficult to distinguish ILC from lobular 
neoplasia (LN), which comprises two subtypes, namely lobular carcinoma in situ 
(LCIS) and atypical lobular hyperplasia (ALH). In Brem et al. study, 23% of 164 
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lesions classified as lobular neoplasia on CNB in fact corresponded to true neoplastic 
lesions (DCIS or ILC) after surgical excision (15), and some authors thus recommend 
excision biopsy when LN is diagnosed on CNB (11, 16, 17).  
Only few studies have examined the correlation between enhancing lesions on MRI 
and pathological examination of the surgical excision specimen (5, 13, 14). Likewise, 
no correlation studies of bilateral mastectomy specimens and MRI findings have 
been reported in this setting. 
The aim of this study was to determine the value of MRI for ILC detection and 
characterization, based on the 2006 BI-RADS criteria, using pathologic examination 
of bilateral total mastectomy specimens as the reference standard. 
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MATERIAL AND METHODS 
Study cohort 
Between 2004 and 2007, 360 patients were diagnosed with ILC in our institution. We 
retrospectively included 15 women, with a mean age of 55 (range 38-66) with CNB-
proven ILC who were treated by bilateral total mastectomy and who underwent pre-
surgical bilateral breast MRI. Among those 15 women, 8 had known risk factors for 
breast cancer including 5 patients with a familial history of breast cancer and 3 
patients who received post-menopausal hormonal therapy for 5 years. Nine women 
were referred to our institution because of clinical symptoms and 6 because of an 
abnormal conventional (mammographic or sonographic) imaging screening. 
Mammograms were abnormal in 11 cases and sonography was abnormal in 13 
cases. Bilateral mastectomy was indicated for surgical and aesthetic reasons in 11 
cases including small breasts (n=7 cases) and optimization of post-operative breast 
symmetry (n=4). Four women opted for prophylactic bilateral mastectomy in order to 
avoid close post-operative follow-up. All decisions were approved by a 
multidisciplinary board of surgeons, oncologists, radiologists, psychologists and 
radiation oncologists (18, 19). All patients had breast reconstruction, immediately in 
14 cases and one year later in one case. 
The mean interval between bilateral breast MRI and bilateral mastectomy was 2 
months (0.5-3.5 months, median of 1.5 months) in 13 cases. In the 2 patients treated 
by neoadjuvant chemotherapy, respective intervals between surgery, pre-
chemotherapy MRI and preoperative MRI were 6 and 1.5 months in one case, and 
12 and 2.5 months in the other case.  
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All patients were alive and free of recurrence after a mean follow-up period of 56 
months (range 28-73). The median period of disease-free survival was 56 months 
(range 28-73). 
Pathology 
Pathological analysis of bilateral mastectomy specimens was based on international 
criteria (20), and was performed by the same senior pathologist with 10 years’ 
experience in breast pathology. Mastectomy specimens were carefully palpated and 
all indurated areas were located (quadrants, superficial or deep area of breast) and 
removed. After that, mastectomy specimens were sliced entirely every centimeter in 
a transversal plane and all dystrophic or indurated areas were removed. Additional 
samples were systematically taken from the nipple skin and behind the areola. 
Three samples of each dystrophic or indurated area were prepared from each tumor, 
including one transecting the maximum diameter of the tumor. All sections were 
analyzed macroscopically and then microscopically after hematoxillin-eosin (HE) 
staining. The maximum diameter and quadrant location of each tumor were recorded. 
In case of several closely located multi-focal or multi-centric tumors, the recorded 
maximum pathological diameter was defined as the largest distance between the two 
most distant lesions. The type of the neoplasm (ILC, IDC, or ductal carcinoma in situ 
(DCIS)) was determined. The quadrant location of lobular neoplasia (LN) associated 
with ILC was also noted and classified as LCIS (lobular carcinoma in situ) or ALH 
(atypical lobular hyperplasia) (17). The quadrant location of benign lesions such as 




• MRI protocol 
Bilateral breast MRI was performed on a 1.5T system (Siemens Avanto®, Erlangen, 
Germany), using a four-channel phased array coil, in keeping with international 
guidelines (21). Sagittal T1 fast spin echo (TR 530msec; TE9.8msec; FOV (field of 
view) of 23 x 17cm, matrix of 384 x 158, slice thickness of 4mm); axial inversion 
recovery turbo spin echo T2 sequences (TR: 9000 msec, TE: 70 msec, TI (time of 
inversion): 120 msec, FOV 32 x 32, matrix 384 x 307, slice thickness: 4mm) were 
acquired. 3D fast gradient echo (Fast Low Angle SHot) fat saturated T1 sequences 
(TR: 11 msec, TE: 5.6 msec, FOV: 28 x 28, matrix 384 x 307, slice thickness: 3D 
3.3mm) were acquired once before and 7 times after bolus injection of 0.2 mmol/kg 
gadoteric acid (Dotarem®, Guerbet, Aulnay, France) at a 3ml/sec rate, flushed with 
20ml of saline administered by a power-injector. The temporal resolution for each 
repetition was 49 seconds. Subtractions were obtained from unenhanced and 
enhanced dynamic 3D fast gradient echo T1 sequences. The last acquisition 
obtained was a sagittal T1 fast spin echo post-gadolinium sequence (TR: 550, TE: 
9.8, FOV: 23 x 17, matrix 384 x 158, slice thickness: 4mm). 
• Image analysis 
All images were retrieved from the local PACS system and analyzed with Advantage 
Windows software version 4.4 (GE Healthcare, Milwaukee, WI, USA) by two 
radiologists (a junior resident with one year of experience and a senior radiologist 
with ten years of experience in breast imaging), who were aware of the diagnosis of 
ILC but blinded to clinical and pathological data. All images were analyzed by 
consensus. In case of discordance, a consensus was reached with a third radiologist 
with 15 years of experience in breast MRI. All images were interpreted according to 
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2006 BI-RADS criteria, including morphological criteria on unenhanced T1 WI and 
T2WI images and enhancement and kinetic profiles following gadolinium chelates 
injection (21-23). The criteria are summarized in Annex 1.  
MRI-pathological correlation 
All MRI were interpreted independently from pathological data, MRI abnormalities 
were matched retrospectively with pathologic data on the basis of their maximum 
diameter and quadrant location described in the pathologic reports. In the two 
patients who received neoadjuvant chemotherapy, maximum tumor diameter was 
evaluated on preoperative MR images. Shape, margins (for masses), distribution of 
non-masslike enhancements and dynamic profiles were evaluated on MR images 
acquired before chemotherapy. The sensitivity and positive predictive value (PPV) of 
bilateral breast MRI for the diagnosis of ILC were calculated, with pathological 
findings as the reference standard. Cases of discordance were analyzed. 
Statistics 
Correlation between the diameters of ILC found on MR and pathological 
measurements taken as gold standard was assessed (Spearman). The ILC diameter 
was used when the neoplasia was unifocal and the largest diameters of all ILC sites - 
from external border to external border of the two most distant lesions- was used 
when the neoplasia was multifocal or multicentric. 
Comparisons of MRI BI-RADS categorical variables between ILC and false positive 
were performed with the Fisher exact test. All statistical analyses were conducted 





Thirty-one foci of ILC were identified on pathology (Table 1). Seven patients had 
unifocal ILC (47%), 6 patients had multicentric/multifocal ILC (40%) and 2 patients 
had bilateral breast cancer (13%), including one patient with one ILC tumor in each 
breast (patient 11), and one patient with 2 ILC in one breast and DCIS in the other 
breast (patient #3). 
Nine (60%) of the 15 patients had lobular neoplasia in association with ILC, including 
the patient (patient #11) with bilateral ILC, who presented with bilateral lobular 
neoplasia. Two patients had ALH and 7 patients had LCIS: all these 9 foci were 
located no further than 1cm from ILC foci. 
MRI-pathological correlation 
All 31 ILC foci were identified on MRI (Table 1), as 28 masses and 3 non-masslike 
enhancements.  Mean MRI diameter of ILC was 27 mm (range 9-65) and 
pathological mean ILC diameter was 23 mm (range 2-60) with excellent correlation – 
Spearman correlation coefficient r=0.92 (95% confidence interval 0.78 – 1); p<0.0001 
(Fig. 1). MRI showed a mean diameter over-estimation of 4.43 ± 4.38mm. All ILC foci 
enhanced following Gd-chelates injection, and all mass lesions had irregular or 
spiculated margins. No ILC presented smooth margins (p=0,02). Ten ILC masses 
showed rim-shaped enhancement (36%), 16 had homogeneous enhancement (57%) 
and 2 had heterogeneous enhancement (7%). Rim-shaped enhancement appeared 
as a distinctive feature of ILC (p=0,039). Of the 3 non-masslike enhancements, one 
had a ductal distribution with stippled internal enhancement, and two had a focal 
distribution with heterogeneous enhancement. The enhancement kinetics of these 31 
ILC lesions, including masses and non-masslike enhancements, were evenly 
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distributed (p=0,36), with 10 wash-out (32.5%), 10 plateau (32.5%) and 11 persistent 
profiles (35%) (Figs. 2 and 3). 
Using 2006 BI-RADS criteria, 11 additional MRI abnormalities in 6 patients were 
wrongly classified as ILC (Tables 1 and 2; Figs. 4 and 5), corresponding either to 
fibrocystic disease (n=8), fibroadenoma (n=1) LCIS (n=1) or DCIS (n=1). Five false-
positive (FP) abnormalities were seen in the ipsilateral breast of 4 patients, one 
patient had 4 contralateral FP abnormalities (patient #8), and one patient (patient #3) 
had one ipsilateral and one contralateral FP abnormality. 
The false-positive abnormalities corresponded to 10 masses (91%) and 1 non-
masslike enhancement (9%) with a mean diameter of 9 mm (range 5-16). All 
enhanced after Gd-chelates injection. The enhancement kinetics of these 11 FP 
lesions corresponded to 1 washout (9%), 4 plateau (36%) and 6 persistent profiles 
(55%). Five FP masses had spiculated margins (50%), 2 had irregular margins (20%) 
and 3 had smooth margins (30%).  Presence of smooth margins appeared as a 
distinctive feature of false positive finding (p=0,039). 
Based on lesion-to-lesion correlation, the FP rate of MRI for ILC diagnosis was 26% 
(11/42). Based on 2006 BI-RADS criteria, the sensitivity of MRI for ILC detection was 
100%. The PPV of MRI for ILC detection was 74% (31/42) overall, with an ipsilateral 
PPV of 83% (30/36) and a contralateral PPV of 17% (1/6). If DCIS was included in 
the calculation of the PPV of MRI for neoplastic foci, the contralateral PPV reached 
33% (2/6). 
When excluding known ILC from the analysis, the PPV of BI-RADS 4 and 5 
additional suspicious images detected on MR for ILC diagnosis was 59% (16/27); if 
DCIS was included as true positive MRI findings, the PPV of MR suspicious images 
reached 63% (17/27). As a result, additional neoplasia foci were detected in 47% 





This MRI pathological study based on bilateral mastectomy specimens confirms the 
known sensitivity of preoperative MRI BI-RADS criteria for ILC detection and 
characterization, previously reported using only pathological examination of CNB or 
lumpectomy specimens (24, 25). However, the sensitivity figures might have been 
overestimated in this study because all radiologists were aware of an existing ILC 
proven on biopsy. MRI features significantly associated with ILC diagnosis included 
absence of smooth margins and rim enhancement, figures similar to those reported 
by Kim et al (26). 
A 26% FP rate was found in our study using 2006 BI-RADS criteria, similar to that 
reported by Berg et al. (25). Fibrocystic disease accounted for most of these false 
positive findings, data similar to that of Baltzer et al. (27). Washout enhancement 
profiles were present in 32% of ILC lesions. Only one focus of fibrocystic disease 
displayed a washout curve, yielding a 91% PPV of washout for ILC. Similar figures 
have been reported by Kinkel et al., suggesting that enhancement kinetics can help 
to distinguish between benign lesions and ILC (28). 
Multifocal and/or multicentric ILC lesions were present in 40% of our patients. All ILC 
sites were detected on MRI, which is rarely the case of conventional mammograms 
or sonograms (3, 25). Moreover, some studies (29, 30) have suggested that the rate 
of local recurrences is higher in patients who undergo re-excision than in patients 
who are initially successfully treated, and our findings therefore imply that 
preoperative MRI could improve local control (12). 
The overall PPV of breast MRI interpreted with 2006 BI-RADS criteria was 74%, a 
figure close to that previously reported (5). However, although the prevalence of 
multifocal/multicentric ILC in our study matched that of previous studies (4, 29), only 
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one contralateral ILC lesion was found in our bilateral mastectomy specimens. We 
acknowledge that we did not include all consecutive patients with ILC who underwent 
breast MRI at our institution, but rather only patients who underwent bilateral 
mastectomy, providing a unique pathological correlation. Our aim was indeed not to 
determine the prevalence of contra-lateral lesion, but rather to confirm the known 
sensitivity of breast MRI in ILC detection not only on biopsy or follow-up data. This 
selection bias could explain in part the low contralateral PPV of breast MRI for ILC 
detection (17%) in our study (14-17, 21). Furthermore, we focused solely on the 
detection of ILC, and not all neoplastic lesions, which further lowered the 
contralateral PPV, DCIS being considered as a false-positive finding. Given the 
100% sensitivity and 26% false-positive rate of breast MRI in our study, atypical MRI 
findings, especially in the contralateral breast, should be pathologically documented 
by second-look US- or MR-guided biopsy. Indeed, several studies confirm that the 
high false positive rate of MRI for ILC detection is still a challenge; our results further 
highlight that suspicious images on breast MRI should be documented on pathology 
before any therapeutic decision (10, 13, 14). 
Lobular neoplasia was strongly associated with ILC on pathological analysis in our 
study. Elsheikh et al reported lobular neoplasia in 27% of patients with invasive 
cancer (IDC and ILC) (16). Some authors have underlined the difficulty of 
distinguishing lobular neoplasms from ILC on CNB (15), while other consider lobular 
neoplasia to be a risk factor or even an indolent precursor of ILC, warranting its 
surgical excision (6). In our study, all foci of lobular neoplasia were located no further 
than 1 cm from ILC foci. Thus, the detection of lobular neoplasia on CNB may point 
to the presence of closely located ILC foci. Besides, it can also explain why 
diameters of ILC on MR were overestimated compared to pathology in most of the 
cases but that the overestimation is relatively constant and mild, and doesn’t 
increase with the diameter of the tumor.  
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One limit of this study is its retrospective design, which did not allow pathological 
examination to be guided by MRI. The small number of patients is also a drawback, 
but bilateral mastectomy is rarely indicated for patients with unifocal, multifocal or 
multicentric ILC. To our knowledge, our study is the first to provide pathological 
correlations based not only on follow-up and CNB but rather on full mastectomy 
specimens. As previously mentioned, the sensitivity of MRI for ILC might have been 
over-estimated, because the radiologists were aware that each patient had at least 
one focus of ILC detected on CNB. Our study design was however not intended to 
provide prevalence data of ILC. PPV of additional neoplastic lesions discovered on 
MRI is of critical importance in the clinical management of ILC patients. Our study 
based on analysis of bilateral mastectomy specimen lead to the detection of new 
sites of tumor for 47% of the 15 patients. Again, these figures could have been 
impacted by the selection bias: only patients who underwent bilateral mastectomy 
were included. Thus the overall contralateral prevalence of ILC cannot be determined 
using this study. On the opposite, our findings suggest that all BI-RADS 4 and 5 
suspicious MR findings shouldn’t be overlooked as suggestive of ILC lesions (26% of 
false positive lesions in our study) and require MR- or US-guided second-look 
biopsies (10, 13, 14). Taken together, our data first confirm that bilateral breast MRI 
allows detection of all ILC foci, even with bilateral mastectomy specimens as the 
reference standard, but at the expense of additional invasive diagnostic procedures 
in order to rule out malignancy in equivocal contralateral abnormalities. 
In conclusion, MRI showed sensitivity figures in-line with previously published data 
for additional ILC sites detection and characterization, using bilateral mastectomy 
specimens as the reference standard. 90% of ILC foci corresponded to masses, all of 
which had irregular or spiculated margins. MRI detected all multifocal, multicentric or 
bilateral ILC foci. However, the high false-positive rate (26%) suggests that 
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Table 1: MRI-pathological correlation analysis based on bilateral mastectomy 
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P: patient number; M: mass; NM: non-masslike enhancement; TP: true positive; FP: 
false positive; HL: ipsilateral to ILC; CL: contralateral to ILC; SEQ: supero-external 
quadrant; SIQ: supero-internal quadrant; IEQ: infero-external quadrant; IIQ: infero-
internal quadrant; UinfQ: union of inferior quadrants; UintQ: union of internal 
quadrants; USupQ: union of superior quadrants; UExtQ: union of external quadrants; 
Rar: retroaureolar location; Irr: irregular margins; Spic: spiculated margins; Ductal: 
ductal distribution; Focal: focal distribution; Rim: rim-shaped internal enhancement; 
Ho: homoegeneous internal enhancement; Het: heterogeneous internal 
enhancement; Stip: stippled internal enhancement; Low: slow signal increase on 
early phase (<2min), < 70% of enhancement ; Med: medium signal increase on early 
phase (<2min), between 70 and 100% of enhancement; Hi: high signal increase on 
early phase (>2min), > 100% of enhancement; Type 1: persistent profile on delayed 
phase; Type 2: plateau profile on delayed phase; Type 3: wash-out on delayed 
phase; ILC: invasive lobular carcinoma; DCIS: ductal carcinoma in situ; FD: 
Fibrocystic Disease; LCIS: lobular carcinoma in situ; FA: fibroadenoma; NA: not 
available; *: The largest distance between the two most distant lesions was collected 
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if ILC was multifocal/multicentric; #: MRI characteristics of the lesions were collected 
before chemotherapy; ##: lesion diameter was collected after chemotherapy  
 
 Table 2: Morphologic and kinetic profiles of ILC and false-positive lesions on 
MRI.     
 ILC FP  
M/NM M 90%  (28/31) 91%  (10/11) 
NM 10%  (3/31) 9%  (1/11) 
M margins 
 
Spic 75%  (21/28) 50%  (5/10) 
Irr 25%  (7/28) 20%  (2/10) 
Smooth 0% 30%  (3/10) 
M enhancement 
 
Rim 36%  (10/28) 0% 
Ho 57%  (16/28) 80%  (8/10) 
Het 7%  (2/28) 20%  (2/10) 
NM distribution Focal 67% (2/3) 0% 
Ductal 33%  (1/3) 100% 
NM 
enhancement 
Het 67%  (2/3) 100% 
Stippled 33%  (1/3) 0 
Kinetics  Type 1 curve 35%  (11/31) 55%  (6/11) 
Type 2 curve 32.5%  (10/31) 36%  (4/11) 
Type 3 curve 32.5%  (10/31) 9%  (1/11) 
 
M: mass; NM: non-masslike enhancement; Spic: spiculated margins; Irr: irregular 
margins; Smooth: smooth margins; Focal: focal distribution; Ductal: ductal 
distribution; Rim: rim-shaped internal enhancement; Ho: homogeneous internal 
enhancement; Het: heterogeneous internal enhancement; Stippled: stippled internal 
enhancement; Curve type on delayed phase: 1: persistent profile on delayed phase; 





Fig. 1- MRI and pathological ILC diameters. Scatter plot showing individual 
measurements of ILC performed on MRI with the pathological diameter of ILC as 












Fig. 2-  50-year-old woman with no personal or family history of breast cancer, with 
bifocal Invasive Lobular Carcinoma (ILC) of the right breast. MR images of the right 
breast showed two round masses with spiculated margins and with respective largest 
diameters of 22 and 15 mm (arrow and arrowhead) on sagittal T1WI (Fig. 2A), 
showing rim-shaped enhancement (arrow and arrowhead in Fig. 2B) after gadolinium 
chelates injection and type 2 curve (Fig. 2C); Lesions were defined as suspicious ILC 
lesions using 2006 BI-RADS MRI criteria. On pathology (x25) after HE staining, both 
tumors showed spiculated margins (arrows in Fig. 2D), and linear arrangement of ILC 
cells (Fig. 2D). 
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Fig. 3- 58-year-old woman with a family history of breast cancer, with a 2-cm unifocal 
non-masslike enhancing Invasive Lobular Carcinoma (ILC) of the right breast. MR 
images of the right breast showed non-masslike enhancement, isointense on sagittal 
T1WI when compared to adjacent breast parenchyma (circle on Fig. 3A). The ILC 
non-masslike lesion exhibited a focal and heterogeneous enhancing pattern after 
gadolinium injection (Arrowheads on Fig. 3B) with a type 1 enhancement curve (Fig. 
3C) that was identified as a true positive on 2006 BI-RADS MRI criteria. On 
pathology (x40) after HE staining, the tumor shows the linear file arrangement of 
infiltrative lobular carcinoma (“Indian file pattern”) (black arrows in Fig. 3D). 
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Fig. 4- 41-year-old woman with a family history of breast cancer, with multicentric 
Invasive Lobular Carcinoma  (ILC) (4 sites of cancer spreading over 35mm) of the left 
breast, with a suspicious ipsilateral MR image: MR images of the left breast showed 
a mass with spiculated margins, hypointense on sagittal T1WI (arrowheads on Fig. 
4A) with intense and homogeneous enhancement (arrow on Fig. 4B) and a type 2 
curve, erroneously classified as suspicious on 2006 BI-RADS MRI criteria (false 
positive image). Pathology (x10) after HE staining showed cystic and dystrophic 
ducts (black arrows) surrounded by fibrosis, consistent with fibrocystic disease (Fig. 
4C).   
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Fig. 5- 51-year-old woman with a family history of breast cancer, with a 15mm 
unifocal Invasive Lobular Carcinoma (ILC) of the left breast and an additional 
suspicious MR image on the ipsilateral breast: MR images of the left breast showed a 
mass with spiculated margins, isointense on sagittal T1WI (arrowheads on Fig. 5A), 
with homogenous intense enhancement after gadolinium injection (arrow on Fig. 5B) 
and type 1 curve; the lesion was classified as suspicious using 2006 BI-RADS MRI 
criteria. Pathology (x40) after HE staining showed ducts filled and distended by non-
cohesive tumoral cells, consistent with lobular carcinoma in situ (Arrow on Fig. 5C). 
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Annex 1:  2006 BI-RADS criteria for MRI (21) 
Mass: A mass is a space-occupying tumor that has three dimensions. Usually, it has 
a visible correlate on precontrast T1- or T2-weighted images; Non-masslike 
enhancement: Non-masslike enhancement means that enhancement occurs in an 
area of the fibroglandular tissue that otherwise appears normal on precontrast 
images. There is no space-occupying effect. The enhancing area usually has no 
correlate on fat-suppressed or non–fat-suppressed T2-weighted images; Type1: 
kinetic curve showing persistant profile on delayed phase; Type 2: kinetic curve 
showing a plateau on delayed phase; Type 3: kinetic curve showing a wash out on 
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Initial phase Delayed phase           Type 
Slow Persistant 1 
 30 
Medium 
Rapid 
Plateau 
Wash out 
2 
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